Gelus N, Hamy F, Bailly C
INSERM Unité 524, IRCL, Lille, France.
Bioorg Med Chem. 1999 Jun;7(6):1075-9. doi: 10.1016/s0968-0896(99)00030-9.
We investigated the interaction of a highly potent acridine-based tat-antagonist with the TAR RNA of HIV-1. The wild type TAR RNA and three mutants with U-->C23, G x C-->C x G26-39 or G x C-->A x U26-39 substitutions were used as substrates to study the molecular basis of drug-TAR RNA complex formation. Melting temperature and RNase protection experiments reveal that the G x C26-39 pair is a critical element for specific major groove recognition of TAR at the pyrimidine bulge. The results provide a rational basis for future design of optimized tat/TAR inhibitors.
我们研究了一种高效的基于吖啶的tat拮抗剂与HIV-1的TAR RNA之间的相互作用。野生型TAR RNA以及三个分别具有U→C23、G×C→C×G26 - 39或G×C→A×U26 - 39替换的突变体被用作底物,以研究药物 - TAR RNA复合物形成的分子基础。解链温度和核糖核酸酶保护实验表明,G×C26 - 39碱基对是嘧啶凸起处TAR特异性大沟识别的关键元件。这些结果为未来优化tat/TAR抑制剂的设计提供了合理依据。